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Abstract
A recent primary drug screen by the University of New Mexico Center for Molecular
Discovery uncovered a novel group of allosteric-modulators of VLA-4 integrins known
as phenothiazines. Phenothiazine family compounds were initially discovered as organic dyes in the 1800’s, the most well-known of which is methylene blue. Relatively
soon thereafter phenothiazines were found to be useful clinically, a trend that has
continued in the century since peaking as antipsychotics in the 1950’s. Today, phenothiazines are still being pursued clinically as seen in a number of recent patents for
phenothiazine use in autoimmune disorders. This study sought to further characterize the newly discovered relationship between phenothiazines and VLA-4 integrin in a
stepwise progression from in vitro experiments to an in vivo animal model. Here, it is
shown that the phenothiazine compound thioridazine causes broad inhibition of adhesion related activity including: the rapid interruption of VLA-4 bound fluorescent
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molecules, the disaggregation of VLA-4 and VCAM-1 attached cells, rapid reduction
in intracellular calcium signaling, and loss of cellular motility to Gαi chemokines.
Furthermore, it is shown that thioridazine treatment can cause a 3-fold increase in
mobilization of murine hematopoietic stem and progenitor cells. Combined, these
data answer forty year old questions about the nature of phenothiazine treatment,
provide insight in to the mechanism of action and provide evidence for the potential
of VLA-4 allosteric modulators in vivo.
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Introduction

Integrins are highly expressed adhesion receptors, critical to microscopic processes
such as cell growth, maturation, differentiation and macroscopic processes such as
embryonic development, immune response, and tissue repair. At first glance is a
seemingly straight forward appearance which dissembles their complexity and function (Figure 1). Crystallography has revealed integrin structure as comprised of two
N-terminus ligand binding domains each extended ≈ 170Å extracellularly by ”leg”
domains which span down through the cell membrane into the cytoplasm (Arnaout
et al., 2005; Luo et al., 2007).

The ”leg” structures are made of

multiple domains which together can collapse, bend, and
twist creating multiple conformations altering both extracellular adhesion and intracellular
signaling. Adding to this com-

(a)

basic

(Lewin et al., 2006)

plexity, the combined ”head”

(b) electron

(c) domain

(Rocco et al., 2008)

(Chigaev et al., 2009)

Figure 1: Integrin Structures

and ”leg” domains make-up distinct α and β subunits. The paired subunits form a multitude of integrins for cell
specific expression, loss of functionality redundancy, and other specialized roles. Currently, there are 24 known αβ integrin combinations formed by 18 possible α and 8
possible β subunits. This study focuses on the α4β1-integrin (Very Late Antigen4, VLA-4) one of many integrins types expressed on hematopoietic cells including
mature leukocytes, progenitors, and cancer cell types (Lewin et al., 2006). VLA4 is crucial to regulating the hematopoietic populations, retaining progenitors in
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the bone marrow for re-population, and in trafficking leukocytes during immune responses (Figure 2). With such important roles in normal physiology VLA-4 is also
involved in the pathogenesis of a number of diseases. In fact, a number of compounds
directly targeting the VLA-4 ligand binding pocket have already been developed and
researched in therapies including, stem cell mobilization, cancer treatment, and autoimmune diseases. Moderate success with these compounds in animal trials, clinical
trials and even FDA approval for some compounds suggests that VLA-4 and other
integrins represent viable therapeutic targets.
Unfortunately, the direct VLA-4 antibodies and small molecule compounds developed to date may not represent the best possible therapeutic options (Cox et al.,
2010). Previous work has demonstrated compounds binding directly to the VLA-4
ligand pocket can displace native ligand but in doing so still retain the integrin in
an activated conformational state (Billard and McIntyre, 2008; Njus et al., 2009).
The retention of the activated conformation by these compounds maintains intracellular signaling capabilities and thus potentially unwanted effects during treatment.
In cancer, for example, static VLA-4 activation is thought to provide growth signals
and resilience against chemotherapy. Efficacy of these direct compounds can also
be affected by different signaling environments within the body. In areas rich with
chemokine and growth factor expression, such as the bone marrow, indirect signaling
alters the affinity with which integrins bind to ligand. Thus, a need exists to find
novel VLA-4 antagonists which could potentially improve therapeutic efficacy over
the current direct VLA-4 antibody and small molecule compounds.
In 2008, a high-throughput flow cytometry screen designed by Larry Sklar and
Alexander Chigaev was conducted to discover allosteric modulators of VLA-4 (Sklar
and Chigaev, 2008).

Among the active compounds were a group of phenoth-
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iazines, a family of drugs with a long history in medicine, known primarily as earlyantipsychotics. This finding may have been the first to demonstrate a connection
between phenothiazines and integrins. Clinical use of phenothiazines for over a cen-

(a) Trafficking

(Alon and Shulman, 2011)

(b) Retention

(Burger and Kipps,

2006)

(c) Signaling

(Lewin et al., 2006)

Figure 2: VLA-4 Activities: (a) Illustrates VLA-4 mediated leukocyte capture and
trafficking within the bloodstream. Capture starts with selectins, a class of adhesion
receptors which cause leukocytes to roll along the lumen of the endothelium. Next,
contact with surface bound chemoattractant molecules along the endothelial lumen
activates VLA-4 integrins causing firm adhesion. The arrested leukocytes then crawl
and extravasate out of the bloodstream. (b) Illustrates VLA-4 mediated homing and
static adhesion of hematopoietic progenitors within the bone marrow. Chemoattractants expressed by marrow stromal cells activate VLA-4 integrins on the progenitor
cells mediating attachment. Static adhesion also occurs creating long term binding
that holds progenitors in the marrow.(c) Illustrates the various outside-in signaling
pathways which are coupled to VLA-4 receptors. VLA-4 adhesion causes conformational changes in the cytoplasmic subunit tails initiating scaffolding of several
signaling and structural proteins. The illustration also demonstrates the capacity
for multiple integrins to consolidate on the cell surface and expand the scaffold.
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tury does however suggest VLA-4 related mechanisms in a number of old case studies
and more recent patents which identify therapeutic potential in cancer, asthma, and
rheumatoid arthritis treatment. Combined the findings from the screen and past
literature suggested phenothiazines could allosterically regulate VLA-4 both in vitro
and in vivo. Therefore, it was the intent here to study a phenothiazine compound
from the 2008 screen in a number of in vitro and in vivo experiments which had
previously only tested direct VLA-4 compounds. It was believed that the chosen
phenothiazine would lead to similar but potentially accelerated and more complete
responses as an allosteric modulator of VLA-4 compared to direct compounds.

1.1

Phenothiazine History

Phenothiazine compounds were first synthesized in the late 1800’s (Mitchell, 2006).
Tricyclic structures containing a central thiazine ring, early phenothiazines such as
methylene blue were first developed as colourants or dyes (Figure 3). In the following
decades it was discovered
that methylene blue could
not only bind biological
tissue but could be used
therapeutically as an an-

(a) Phenothiazine (b) Methylene blue (c) Thioridazine

timalarial, antipsychotic,

Figure 3: Phenothiazine Structures.

and analgesic. The prescribed use of phenothiazines for psychiatric disorders has
been widespread in the century since. At least sixty unique phenothiazine compounds with different substitutions were developed for clinical practice (Jones, 1996).
Such expansion and use led to the discovery and rediscovery of many therapeutic
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purposes for phenothiazines including; immunomodulatory, chemotherapeutic, antipruritc, antiemetic, antifungal, antibacterial, antihelmic, and antimalarial. The
broad range of biological activity suggests numerous possible targets and mechanisms of action. Based on measurable increases in metabolite concentrations, early
clinical efficacy was correlated to the blockade of neurotransmitter receptors, namely
dopamine and serotonin (Sudeshna and Parimal, 2010). A later study demonstrated
that various side groups altered muscarinic receptor affinity and correlated inversely
with extra-pyramidal side effects (Snyder et al., 1974). Recent reviews indicate that
the specific phenothiazine target of action is not clear. The authors consider and
discuss the the multiple enzymatic, redox, and signaling effects which can all vary
depending on cell type and the numerous phenothiazine substituents (Mitchell, 2006;
Sudeshna and Parimal, 2010; Kinross-Wright, 1967) Thus, phenothiazines have a
well-established history of clinical efficacy yet have a number of paradoxes concerning their target site and mechanism of action.
The phenothiazine family’s long existence and wide ranging therapeutic efficacy
has led to a number of observational and case studies documenting unexpected clinical effects. Some of these studies indicate a potential connection to integrin modulation. In one group of studies, multiple investigators reported atypical lymphocyte
presence in the peripheral blood of phenothiazine treated patients (Fieve et al., 1966).
In one of these studies, phenothiazine treated schizophrenic and non-schizophrenic
patients averaged a ≈ 12% increase in atypical lymphocytes over non-phenothiazine
treated patients. When this research was conducted in 1966, with hematopoiesis
not yet fully understood, the atypical lymphocytes were described as dividing and
differentiating lymphocytes which may have ”escaped” into the blood. The pictures
and descriptions from this research indicate that atypical lymphocytes are what we
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know today as hematopoietic progenitor cells (HSC’s) escaped from spleen or bone
marrow. Thus, these studies suggest that phenothiazines may somehow alter HSC
homing or mobilization but the mechanism of action is unclear.
A second set of case studies have implicated phenothiazines in the treatment of
cancer. These studies detail miraculous recoveries in patients whom were provided
phenothiazines as antidepressants or antiemetics following chemotherapy (Jones,
1996). Marked improvements were seen in numerous types of cancer; bronchial,
breast, squamous cell, even in cases where chemotherapeutic resistance had set in.
These case studies have led to a number of in vitro experiments showing that phenothiazines alone or synergistically with anticancer drugs cause necrosis and apoptosis in cancer cell lines (Zhelev et al., 2004; Lialiaris et al., 2009; Darkin et al., 1984).
More recently phenothiazine efficacy has been expanded in a number of patents
claiming phenothiazines as serotonin receptor antagonists to treat immunopathologies including, asthma, rheumatoid arthritis, and other inflammatory diseases (Roth
et al., 2005, 2009; Roth and Zope, 2009; Urbahns et al., 1999). While these studies mention other potential targets rather than integrins, the modulation of VLA-4
has been linked to all of these pathologies. Thus, decades of expanding clinical use
indicates numerous potential therapies with phenothiazines where VLA-4 allosteric
modulation may potentially contribute to the mechanism of action.

1.2

VLA-4 in vitro

in vitro studies have identified three independent conformational features to describe VLA-4 integrins; mechanical form (bent or extended), affinity state of the
ligand pocket, and occupancy of the binding pocket (Chigaev et al., 2009). The sub-
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classifications, bent or extended, high affinity or low affinity, bound or unbound, can
be combined and arranged to postulate eight different physiological conformations.
Different in vitro methods have been used to study each feature; florescent resonance
energy transfer experiments to characterize mechanical form, flow cytometry experiments to characterize affinity and ligand occupancy, and shear flow experiments to
characterize adhesion (Kim et al., 2003; Alon and Ley, 2008; Chigaev et al., 2001).
Combined these methods have established how the conformations are regulated both
independently and together. In the cases of affinity and extension both have been
shown to be controlled by inside out signaling. While each can be regulated independently G-protein coupled receptor signaling cascades have been shown to cause both
rapid unbending and increased affinity (Chigaev et al., 2007). This type of signaling
can be initiated in vitro with chemokines, such as SDF-1α and fMLF, acting through
their respective Gαi receptors CXCR4 and FPR, to mediate contact events including
trafficking, rolling, tethering and firm adhesion. The third conformational feature,
a structural change induced by binding pocket occupancy is highly independent of
both affinity, extension and G-protein coupled inside-out signaling. Understanding
the independence of this conformational change was the basis for the 2008 screen
which identified the phenothiazine family.
The screen used the probe HUTS-21, which conditionally binds VLA-4 when ligand occupied, to indirectly monitor occupancy of the binding pocket. HUTS-21 is a
fluorescent antibody which targets a ligand induced binding site (LIBS) on the hybrid
domain of β1 subunit. Prior to the screen, in vitro experiments determined binding of HUTS-21 was directly correlated with ligand occupancy and uncorrelated to
inside-out signaling (Chigaev et al., 2009). This initially led to an effort to reclassify
existing VLA-4 compounds as either agonists or antagonists and as direct or indirect
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modulators. The subsequent experiments indicated that many compounds known to
modulate VLA-4 were in fact direct competitors to the ligand binding pocket and
exposed the LIBS to HUTS-21 (Njus et al., 2009). The screen was thus designed to
address the need for novel compounds which could obscure the LIBS. The results
showed that phenothiazine family compounds could reduce the fluorescent signal
generated by HUTS-21 binding to the VLA-4 LIBS, thus creating a need for further
studies to establish the ability of phenothiazines to modulate VLA-4 adhesion.

1.3

VLA-4 Pathologies

The broad expression of VLA-4 across different cell populations indicates its importance in human systems. Loss of β1 or α4 are both embryonic lethal in knockout
mice (Imai et al., 2010; Lewin et al., 2006). In keratinocytes conditional β1 knockout
mice showed deficits in basal lamina assembly resulting in alopecia and skin blistering. Other conditional knockouts aimed at hematopoietic cells showed altered HSC
homing, loss of differentiation, and increased progenitor populations in the spleen
and peripheral blood. Counter to VLA-4 reduction, over-expression and/or overactivation of VLA-4 has been linked to the inflammation responsible for autoimmune
pathogenesis (Jackson, 2002). Inflammation is often the result of abnormal leukocyte
recruitment and accumulation at affected organs and tissues. Both the recruitment
and accumulation are thought to be largely VLA-4 and integrin mediated. A VLA4 drug, natalizumab, an α4 antibody, was in fact FDA approved in 2004 to treat
two autoimmune diseases, multiple sclerosis and Crohn’s disease (Johnson, 2007). In
multiple sclerosis natalizumab is thought to block VLA-4 mediated tethering and extravasation of leukocytes across endothelial cells at the blood brain barrier decreasing
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inflammation and subsequent myelin loss. Unfortunately while promising in clinical
trials at lowering the incidence of lesions in both Crohn’s and multiple sclerosis, side
effects, namely the development of PML (progressive multifocal leukoencephalopathy) in a few patients has led to restricted guidelines for use. Development of PML
is typically related immunosuppression allowing a latent virus to attack the brain.
Concern over immunosuppression has halted a number of other integrin antibodies
in clinical trials as well including valategrast, an orally delivered VLA-4 antagonist
showing promise in an asthma trial (Woodside and Vanderslice, 2008). Regardless,
these integrin targeted drugs such as natalizumab along with the knockout studies
have therapeutically established VLA-4 in autoimmune pathogenesis. Thus, there is
a clinically established relationship between VLA-4 and autoimmune diseases, phenothiazines being patented for clinical therapy in the same diseases, and in vitro
evidence of phenothiazines modulating HUTS-21 antibody from the β1 subunit of
VLA-4.

1.4

Mobilization

While, both integrin and phenothiazine based treatments are being actively pursued
for autoimmune disorders, hematopoietic stem cell (HSC) mobilization is an area
where only VLA-4 small molecule drugs are being tested. The HSC population is
made up of several groups of varying long term and short term undifferentiated cells
and the early progenitors for each blood cell lineage (Challen et al., 2009). These
progenitor populations are critical and must be replenished and maintained throughout life to facilitate hematopoiesis. The niche and center for this HSC growth is the
bone marrow. Under normal conditions these early progenitor and undifferentiated
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stem cell populations can also be found circulating in the peripheral blood. The relative numbers in the periphery are low but fluctuate with steady-state homeostatic
processes including circadian rhythm, injury, thymus re-population and marrow overpopulation (Lane et al., 2009; Lucas et al., 2008). The major mechanisms regulating
the release and homing of these cells include maturation based receptors such as
CD34, chemokines such as stem cell factor and integrins. Clinically, acquisition of
these early undifferentiated HSCs has become an essential step in transplantation
therapies to ensure successful engraftment. Pharmaceutical induced mobilization
is now preferred over direct bone marrow harvesting due to higher undifferentiated
stem cell yields, faster hematopoietic repopulation, and technical simplicity. These
treatment goals along with research of the HSC population have led to a number of
potential compounds for mobilization. The three major classes of compounds currently in use are granulocyte colony stimulating factor (G-CSF), AMD3100/3465,
and VLA-4 small molecules.
G-CSF is a growth factor and the predominate choice for HSC mobilization. It
is administered on consecutive days in order to first induce a large increase in the
HSC population (Wagers et al., 2002; Broxmeyer et al., 2005). On day four to five
of treatment the overgrown HSC population releases from the bone marrow into
the periphery creating 1000-fold increases in the circulating HSC population. Such
expansion of the relatively small stem cell population makes G-CSF a very advantageous mobilizing agent. However, wide patient variability along with comparison
studies which have shown physically harvested marrow to be better for long term
hematopoietic repopulation have raised concerns about G-CSF. A group from Stanford University lead by Irving Weissman believed expression of adhesion molecules
were likely altered in G-CSF mobilization and causing the issues with repopulation
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(Wagers et al., 2002). They measured expression of multiple α-integrin subunits as
well as β1 on isolated bone marrow and peripheral blood stem cells following 0, 2
and 4 days of G-CSF stimulation. They found reduced α4 and β1 expression after 4day G-CSF stimulation, and concluded the decrease in integrin expression in G-CSF
mobilized cells was associated with the reduced repopulation capacity. Thus, while
G-CSF mobilization is largely based on population expansion there is evidence that
VLA-4 expression is also involved in HSC mobilization homing capacity.
AMD compounds were originally developed as targets of the HIV co-receptor
CXCR4. The bicyclam AMD3100 (Plerixafor) was withdrawn as a candidate in
HIV therapy but has since become known as a CXCR4 chemokine receptor antagonist (Broxmeyer et al., 2005). The CXCR4 receptor is broadly expressed across
hematopoietic cells, including HSC’s. It is coupled to Gαi which produces both calcium and PI3K signals in response to its predominant ligand, stromal cell-derived
factor-1 (SDF-1, CXCL12). SDF-1 binding to CXCR4 not only causes the activation
of VLA-4 but also cellular polarization leading to directional movement towards soluble SDF-1 gradients. The expression of SDF-1 chemokine is regulated by hypoxiainducible factor 1α, a transcription factor which responds to low oxygen conditions.
Ischemic lesions are for example known to produce SDF-1 causing migration to the
injury. Under normal circumstances, the bone marrow is also a relatively hypoxic
environment which induces a basal level of SDF-1 expression. in vitro experiments
testing cell migration in response to SDF-1 eventually led to the use of AMD3100. in
vivo the initial AMD3100 HSC mobilization study demonstrated peak release after
one hour with mobilized progenitor counts and repopulation similar to 4 day G-CSF
treatment. When treatments were combined, a synergistic increase was observed in
4 day G-CSF mice treated for 1 hour with AMD3100. It’s plausible the synergy
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is related to reduced VLA-4 expression by G-CSF but it could also be due to the
release of the G-CSF expanded HSC’s which are being held in place by an SDF-1
gradient. AMD3100 has been shown to block both the SDF-1 chemotactic gradient
and activation of integrins so it is uncertain which effect is more important in mobilization. Regardless, AMD3100 has proven that disruption of the CXCR4 receptor
is a viable strategy for HSC mobilization.
VLA-4 mobilization has been researched for almost twenty years. The study by
Weissman et. al. mentioned earlier reported that α2-6 and β1 integrins are all expressed by HSC populations (Wagers et al., 2002). The study also reported that an
α4 antibody can significantly reduce bone marrow homing in mice. A study published a decade earlier in 1993 reported that α4 antibody can also cause a 200-fold
increase of peripheral HSC’s in primates (Papayannopoulou and Nakamoto, 1993).
More recently α4 mobilization has been reported to cause continuous high levels of
circulating HSC’s found in multiple sclerosis patients treated with Natalizumab (Jing
et al., 2010; Zohren et al., 2008). Unexpectedly, chronic Natalizumab treatment was
also reported to cause a ≈15 fold HSC population increase in patient bone marrow
compared to healthy donors. The cause is uncertain, it could be due to a disruption
in growth regulation mediated by α4 or possibly a side effect of blocking leukocyte
homing associated with inflammation in autoimmune disease. Even more recently a
novel VLA-4 targeted molecule, BIO5192 was used to mobilize HSC in mice. Data
was collected over a 24 hour collection period, with peak HSC counts after 3-6 hours.
BIO5192 is a small molecule inhibitor based on the LDV sequence of fibronectin and
known to expose the β1 LIBS (Leone et al., 2003). It has high selectivity for both
active and inactive α4β1, with higher affinity than the natural ligand (< 10 µM Kd ).
Interestingly, BIO5192 was reported to be synergistic with both AMD3100 and G-
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CSF separately or combined. This suggests there are separate mechanisms by which
each G-CSF, BIO5192 and AMD3100 operate which are all uniquely important in
HSC mobilization. Thus, taken together VLA-4 represents a proven target for HSC
mobilization and therefore represents a potential therapeutic target for novel in vivo
phenothiazine treatment.

1.5

VLA-4 and Cancer Therapy

In hematological cancers, drug resistance is a major factor which determines patient
outcome. Often resistance may go undetected until relapse. This is especially true in
minimal residual disease where small numbers of surviving cancer cells can propagate
an often resistant malignancy. Two major contributors to drug resistance are location, which affects the effective concentration of drug delivery, and growth-survival
signaling, which can overcome a drug’s mechanism of action. The bone marrow niche
which normally harbors HSC’s and facilitates hematopoiesis is thought to be a safe
harbor for cancer cells contributing to both aspects of resistance. The niche is isolated from major blood flow and provides necessary ligands to facilitate at least three
separate pro-growth pro-survival signaling pathways (McCubrey et al., 2008). Overtime the acceptance and understanding of this niche has broadly expanded treatment
design in hematological cancers. Compounds which affect cells in the niche including compounds targeting integrins are now being tested in a multifaceted approach
designed to increase efficacy of chemotherapeutic agents.
Integrins are thought to affect three major factors in niche mediated cancer resistance: homing of cancer cells to the bone marrow, retention of cancer cells in the
niche, and adhesion mediated pro-survival signaling. The contribution of homing to
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malignancy was shown in a study which compared leukemic progression between a
wild-type acute lymphoblastic leukemia cell line, Nalm-6, expressing VLA-4 and a
mutated version of the cell line lacking β1 (CD49d) expression. All mice injected
with Nalm-6 (wt) cells developed cancer involving hind-limb paralysis with an average event free survival of 30 days. In mice injected with Nalm-6 (β1− ) only one
out of twelve mice developed hind-limb paralysis and six mice were event free after
100 days. Furthermore within the bone marrow VLA-4 integrin also contributes to
the retention of these cancer cells. Since, many hematologic cancers tend to be mutated forms of early HSC progenitors they are retained similarly to the normal HSC
population. VLA-4 expression has been confirmed on numerous acute lymphoblastic
leukemia, acute myeloid leukemia, and multiple myeloma cell lines as well as patient cells (Mudry et al., 2000; Noborio-Hatano et al., 2009; Matsunaga et al., 2003).
The natural ligands for this VLA-4 mediated retention are fibronectin in the bone
marrow extracellular matrix and VCAM-1 expressed on bone marrow stromal cells.
While attachment to these stromal cells serves to isolate the cancer cells from the
bloodstream it also contributes to another consequence of VLA-4 adhesion. Binding
to ligand also propagates outside-in signaling through a conformational change in
the cytoplasmic tails of each VLA-4 subunit. When bound the cytoplasmic tails of
VLA-4 untwist allowing the scaffolding of numerous signaling kinases (Figure 2C).
In ALL, AML and MM cell lines, binding to fibronectin has been show to activate
the pro-survival PI3K/Akt/BcL-2 pathway. Binding to VCAM-1 on marrow stromal cells is known to activate ILK which induces phosphorylation of STAT3, Akt,
and ERK, or more simply three separate pro-growth pro-survival pathways. Thus,
evidence exists for multiple mechanisms by which VLA-4 can contribute to drug resistance in hematological cancers.
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The potential for hematological cancer treatment directed at VLA-4 has been
demonstrated both in vitro and in vivo. in vitro studies have reported the ability
of VLA-4 directed compounds to overcome the anti-cancer drug resistance derived
from binding fibronectin or stromal cells in AML, MM, and ALL (Mudry et al.,
2000; Matsunaga et al., 2003; Zeng et al., 2009; Noborio-Hatano et al., 2009). In
animal studies at least two different approaches have been tested. One of these studies reported that an antibody to VLA-4 combined with Ara-C increased the overall
survival of mice infected with patient AML cells. In multiple myeloma a protease
inhibitor, bortezomib, which is thought to down-regulate the β1 subunit has shown
potential in fighting what is a very drug resistant plasma cell cancer (Noborio-Hatano
et al., 2009). In fact, bortezomib is now being tested in a number of clinical trials
as a potential treatment in MM where to date 10-year survival is almost zero. However, while bortezomib is in clinical trials treatment with other antibodies to VLA-4
and VLA-4 small molecule compounds has not yet reached the broad acceptance
needed for clinical trials. A recent review has suggested a number of reasons for
the delay (Cox et al., 2010). First, the current clinical drugs natalizumab and efalizumab exhibit a number of side effects including the aforementioned risk of PML.
Second, neutralizing antibodies have been shown to develop against antibody-based
treatment with natalizumab. Lastly, the small-molecule integrin targeted drugs were
developed without extensive knowledge of the role of integrin receptors creating concern over potential agonist properties. Thus, while there is evidence VLA-4 is useful
in the treatment of hematological cancer known antibodies and small molecules are
not considered ideal clinical candidates.
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1.6

Experimental Approaches

The 2008 high-throughput screen served to establish the previously unknown relationship between VLA-4 integrin and phenothiazines. The long clinical history of
phenothiazines and decades of research on VLA-4 seems to further confirm this relationship. Because of this and because these compounds represent the first known
allosteric modulators of VLA-4 many questions were raised concerning the direct
nature of this relationship. To investigate these questions a number of vitro and
in vivo experiments were performed. The first set of experiments asked whether
phenothiazines could have the same impact on integrins in the high affinity integrin
state as compared to the low affinity integrin state tested in the screen. These studies were carried out using previously established flow cytometry methods to monitor
dissociation of ligand in real-time following integrin affinity activation through Gαi
signaling. The next experiments sought to answer whether the phenotiazine compounds were causing ligand dissociation by altering intracellular signaling. Again
flow cytometry was used, this time to monitor real-time changes in intracellular calcium concentration as an indicator of signaling. The next investigation was whether
phenothiazine could impact cellular homing as seen by aforementioned studies using AMD3100. This was tested in vitro using chemotaxis assays to assess cellular
migration towards chemokines. The questions then shifted to whether or not phenothiazines could have a measurable impact on a VLA-4 integrin mediated process
in vivo. Because of the recent success with small molecule VLA-4 inhibitors on HSC
mobilization, treatment with phenothiazine was expected to have similar results.
Therefore, mobilization was assessed in mice to determine if phenothiazine could
increase the circulating HSC population. For this study phenothiazine was injected
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one hour prior to blood collection and results were compared to similar treatment
with the positive control AMD3100. Finally, because of VLA-4’s role in the cancer
niche and case studies suggesting phenothiazines played a miraculous role in overcoming drug resistant cancers the question was asked whether phenothiazine could
potentiate the effects of anti-cancer drugs by blocking integrins. To test this hypothesis an in vitro study was designed using a B-cell acute lymphoblastic leukemia cell
line seeded in culture dishes on the VLA-4 ligand VCAM-1 and measuring whether
or not phenothiazine increased cell death caused by the anti-cancer drug cytosine
arabinoside. Together these experiments should help to determine the impact of
phenothiazines as an allosteric modulator of VLA-4 and potentially provide insight
towards future therapeutic treatments.

2
2.1

Methods
Materials

VLA-4 specific ligands LDV and LDV-FITC the VLA-4 specific ligands were synthesized at Commonwealth Biotechnologies (Chigaev et al., 2008). fMLF (N-formylL-methionyl-L-leucyl-L-phenylalanine) was purchased from Sigma-Aldrich. Human
recombinant CXCL12-SDF-1α was from R&D Systems. Thioridazine and AMD3100
were purchased from Tocris Biosciences. For the animal study injection solutions
were prepared to 200 µL for 30 g mice and adjusted to mass for each mouse individually. Thioridazine was prepared from a 10 mM stock in DMSO diluted to yield
a 2.5% DMSO solution in sterile saline. AMD3100 was prepared fresh each day,
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weighed and diluted in sterile saline. The vehicle solution was 2.5% DMSO in sterile
saline. Chemotaxis chambers were polycarbonate transwell inserts designed to create
an upper and lower chamber with 8.0 µM pores for cell migration manufactured by
Corning (Product #3422). Cytosine arabinoside (Ara-C) and sodium bicarbonate
were purchased from Sigma-Aldrich. Recombinant human VCAM-1 Fc chimera was
from R&D Systems. HBSS media was from Gibco. Fluo-4, AM Calcium dye was
purchased from Invitrogen.

2.2

Cell lines and Transfectant Constructs

The human histocytic lymphoma U937 cell line was originally purchased from ATCC.
The transfected lines U937FPR (formyl peptide receptor) and U937FPR∆ST, a nondesensitizing mutant of FPR, were a gift from Dr. Eric Prossnitz created as described
previously (Kew et al., 1997). B78H1 cells subcloned from the murine melanoma
B16 cell line were previously transfected with human VCAM-1 as described (Zwartz
et al., 2004). The human B cell precursor leukemia NALM-6 cell line was originally
purchased from DSMZ.de. All cells were cultured in complete RPMI 1640 supplemented with L-glutamine, penicillin, streptomycin, non-essential amino acids and
fetal bovine serum.

2.3

Mice

Male C57Bl6 mice weighing 24-30 g, age 9-13 weeks were purchased from Jackson
Laboratories. Mice were acclimated to the animal facility for at least one week, kept
on a 12 hr light/dark cycle and fed a standard diet. Experiments were conducted
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between 10:00 AM and 12:00 PM (lights on 7:00 AM). Procedures used in this
study were conducted by authorized personnel and approved by the Institutional
Animal Care and Use Committee. Mice were injected intraperitoneally with vehicle,
thioridazine (1.25 mg/kg), or AMD3100 (5 mg/kg) 1-hour prior to blood collection.
Prior to and throughout blood collection mice were anaesthetized using isoflurane
and monitored for sensitivity. Blood was collected by heart puncture and continued
to exsanguination (1-1.4 mL). Blood was collected in a syringe containing 100 µL
heparin and immediately mixed into a conical tube containing an additional 100
µL heparin to prevent clotting. Total blood volume collected was recorded for each
mouse.

2.4

Small Fluorescent Molecule LDV-FITC Probe

Real-time binding and dissociation experiments using the LDV-FITC probe have previously been described (Chigaev et al., 2008; Zwartz et al., 2004). In short, cells from
culture were washed with serum-free RPMI 1640, resuspended at 1x106 cells/mL in
complete media and placed on ice. For each experiment 500 µL cells were transferred
into a round-bottom sample tube containing a 5x2 mm magnetic stir bar (Big Science, Huntersville NC) and incubated in a 37◦ C water bath for at least 5 min. After
incubation, samples were analyzed on a FACScan flow cytometer using CellQuest
software (Becton Dickinson, San Jose, CA) for up to 1024 seconds, while at 37◦ C
and stirred at 300 rpm. Baseline autofluorescence data was collected continuously for
30-120 seconds followed by addition of 8 nM LDV-FITC. The fluorescent signal after
addition of the probe was monitored and allowed to reach a stable plateau (80-120
seconds). At this point GPCR ligands, either 100 nM fMLF or 12.5 nM SDF-1α
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were added and monitored for up to an additional 200 seconds.

2.5

Intracellular Calcium Mobilization

For reference this assay has previously been described (Chigaev et al., 2001). In
summary, first U937∆FPR cells were washed and resuspended at 5x106 cells/mL in
HEPES buffer (110 mM NaCl, 10 mM KCl, 1 mM MgCl2, 1.5 mM CaCl2, 30 mM
HEPES, 10 mM glucose, 0.1% HSA, pH 7.4). The cells were then labeled with fluo-4,
a green fluorescent calcium dye, at a concentration of 5 µg/mL for 30 minutes. After
labeling the cells were resuspended at 1x106 cells/mL in HEPES buffer and stored on
ice until used in experiments. For each experiment 500 µL of U937 cells were added
to round-bottom sample tubes each containing a 5 x 2 mm magnetic stir bar and
incubated at 37◦ C for 3 minutes. After incubation the samples were analyzed on the
flow cytometer (FACScan). Samples were stirred continuously at 300 rpm and kept
at 37◦ C. Data was collected as a measure of mean green fluorescence/second. For
each sample approximately 30 seconds of baseline signal was collected followed by
the addition of 100 nM fMLF. Following activation with fMLF data was collected for
3 additional minutes. In blocking experiments 1.25 µL DMSO or 25 µM thioridazine
was added 90 seconds after the addition of fMLF. In pre-activation experiments
DMSO or thioridazine was added at the beginning of the 3 minute incubation period.

2.6

Cell Aggregation Assay

For reference this assay has previously been described (Chigaev et al., 2008; Zwartz
et al., 2004). In summary, first cell lines U937∆ST, U937∆FPR and B78H1 (har-
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vested with 1 mM EDTA) were resuspended in separate 50 mL conical tubes using
serum-free RPMI-1640 to remove any serum from the cells. Next, the cells were
centrifuged at 1200 rpm for 5 min and aspirated until approximately 25 µL of supernatant remained on the cell pellets. At this point the U937 cell lines were stained with
red fluorescent PKH26GL dye and the B78H1 cells with green fluorescent PKH67GL
dye according to the manufacturer’s instructions (Sigma-Aldrich, 2010). After staining, cells were resuspended in RPMI complete media at concentrations of 3x106
cells/mL for B78H1 and 1x106 cells/mL for the U937 cell lines and kept on ice until
used in assays. Next, the flow cytometer (FACScan) was prepared for acquisition by
analyzing the red and green stained cells individually or mixed together. Discrete
populations were set-up for the green FL1 (B78H1 cells), red FL2 (U937 cells), and
aggregate fluorescent signals (Figure 4). A gate was then created for the aggregate
cell population allowing the acquisition of total events/second. Following instrument
set-up, 500 µL B78H1 and 500 µL U937 cells were added to round-bottom sample
tubes each containing a 5 x 2 mm magnetic stir bar. Sample tubes were then placed
in a 37◦ C water bath for at least 5 min. After incubation tubes were attached to
the flow cytometer while resting in a water bath maintained at 37◦ C on top of a
magnetic stir plate set to 300 rpm. Aggregation data was then collected for up to
1024 seconds during which time sequential additions of compounds were made to
stimulate or inhibit aggregation.

2.7

Chemotaxis Assays

From culture, cells were pelleted at low speed in a centrifuge, 7 min at 1000 rpm,
decanted, and washed in complete RPMI 1640 media to improve starting viability.
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(a) Gating

(b) Event Data

Figure 4: Aggregation Methods. (a) Gating schematic for positive selection of
U937-B78H1 aggregates; (b) Representative histogram of raw aggregation data displayed as number of events per bin.

Next, cells were counted using a Vi-CELL XR (Beckman-Coulter) automated cell
counter and resuspended to approximately 2x106 cells/mL. Then, 100 µL aliquots of
cells were pipetted in succession into transwell inserts. Additional 100 µL aliquots
were also collected and re-counted to determine average load. The inserts containing
cells were then carefully placed into the wells of 24-well plates (Figure 5). Each platewell was prepared with 600 µL of room temperature complete RPMI media containing
either chemoattractant or PBS. For inhibition assays, thioridazine or AMD3100 were
immediately added to the transwell inserts following cell addition. Drug concentration was based on the 100 µL/chamber volume in the inserts. Chemotaxis plates were
then incubated for four hours at 37◦ C with 5%CO2 . After four hours, inserts were
removed from all wells and 225 µL sample was collected from each bottom well after
uniform mixing. Each 225 µL sample was then diluted into 450 µL PBS and counted
using a Vi-Cell XR automated cell counter. Percent migration was determined for
each well from the ratio of the total cell/mL count at the end of experiments to the
average viable cell/mL count from the beginning of the experiments.
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(a) Experiment schematic

(b) Neutrophil chemotaxis

(Lokuta et al., 2007)

Figure 5: Chemotaxis Methods. (a) Illustrations of the assembled chemotactic apparatus and cellular migration through the transwell pores; (b) Microscopic
visualizations of neutrophils undergoing chemotaxis.

2.8

Blood Processing and CFU Plating

Blood collected from mice (see above) was processed according to the protocol recommended by StemCell Technologies (StemCell, 2005). Prior to processing, blood
was stored at room temperature as collected in 15 mL conical tubes. In brief, blood
samples were first lysed in 10-12 mL ammonium chloride lysis buffer (StemCell Technologies) for 10 min on ice. The conical tubes were then centrifuged for 7 min at 1200
rpm. The supernatants were then aspirated to approximately 1 mL and washed with
6 mL PBS (Gibco). The conical tubes were again centrifuged for 7 min at 1200 rpm.
The supernatants were aspirated to 0.5 mL and washed with 6 mL IMDM-2%FBS
(Sigma). Once again the conical tubes were centrifuged for 7 min at 1200 rpm. The
supernatants were aspirated to approximately 50 µL and the remaining pellets were
re-suspended in 600 µL IMDM-2%FCS (StemCell Technologies). 56.5 µL from each
sample was added to 562.5 µL PBS for nucleated cell enumeration using a Vi-Cell
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XR automated cell counter. The measured total cell/mL counts were adjusted for
volume collected to determine the white blood cells/mL count. Next, samples were
centrifuged for 5 min at 1400 rpm, aspirated and re-suspended in IMDM-2%FCS to
achieve 2 − 3x106 cells/mL based on the total cell/mL count. 56.5 µL aliquots of
these new solutions were again diluted in 562.5 µL PBS for counting. These cell
counts were the established load counts used to determine CFU/mL. 300 µL of each
load sample was then added to a tube containing 3 mL MethoCult (StemCell Technologies) and vortexed for 20 seconds. 1.1 mL of the resulting MethoCult-cell mix
was plated in p35 dishes (2 per sample) and incubated at 37◦ C with 5%CO2 . Colony
forming cells were counted 14 days later at 10x magnification.

2.9

B-ALL - VCAM-1 cell viability assay

These experiments were based on previously established methods (Matsunaga et al.,
2003; Zeng et al., 2009). In brief, rVCAM-1 was reconstituted in 100 µg/mL PBS and
diluted 1:100 in 0.1 M sodium bicarbonate in HBSS. 100 µL of the resulting solution
or a VCAM free solution was added to each well of a 12-well plate and incubated at
4◦ C for 2 hours. Next, from culture Nalm-6 cells were washed with serum-free RPMI
1640 resuspend at 0.5x106 cells/mL in complete RPMI 1640 media. For each well
1.5 mL of cells were added followed by DMSO, thioridazine or 2 µM Ara-C. After
24-hours cell viability was assessed using a Vi-CELL XR automated cell counter.
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2.10

Analysis

Flow cytometry experiments were conducted using a FACScan flow cytometer and
Cell Quest software (Becton Dickinson, San Jose, CA). Data from the real-time
experiments was converted to mean-FL1H versus time using FCSQuery software
(Dr. Bruce Edwards, University of New Mexico). Data from the cell aggregation
assay was converted to number of aggregate events/bin using Hyperview software
(Dr. Bruce Edwards, University of New Mexico). Chemotaxis, CFU and viability
data was processed with Microsoft Excel and GraphPad Prism. CFU counts were
averaged across two plates for each mouse and normalized based on the load count
to give CFU/1x106 cells. That ratio was then normalized to the CFU/mL count
based on the total white blood cell count mentioned earlier. Representative images
of AMD3100 and thioridazine colony forming cell plates were collected using a darkfield microscope equipped with a CCD camera at 4x magnification. All graphs and
kinetic analysis were generated with Prism 4.0 (GraphPad Software).

3

Results

Previously, five phenothiazine compounds were selected from the 2008 screen and
tested in a flow cytometry assay for the ability of each phenothiazine to induce dissociation of a florescent VLA-4 ligand, LDV-FITC, from U937FPR∆ST cells (Chigaev et al., 2011). The EC50 for dissociation of each phenothiazine compound was
determined using five serial concentrations. All five compounds had an EC50 in the
range of 3.2 − 13.0µM. Due to this narrow range for integrin modulation the best
candidate compound for this research was instead chosen based on highest clinically
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safe dose. Background literature indicated the compound thioridazine would allow
the highest dose among the five compounds with a published 800 mg/day maximum
dose and clinically relevant doses from 2-36 µM plasma concentration (Zhelev et al.,
2004; Hartigan-Go et al., 1996; Kemper et al., 1983). Coincidentally, in addition
to the highest clinically administered dose, thioridazine also had the lowest EC50 of
3.2 µM of the five compounds in the aforementioned assay. Hence, thioridazine was
chosen as the phenothiazine compound for this research.

3.1

Thioridazine strongly dissociates ligands from Gαi induced high affinity VLA-4 integrins.

The aforementioned assay established the ability of thioridazine to induce dissociation of the LDV-FITC probe under basal integrin affinity (Chigaev et al., 2011).
Here thioridazine was tested against Gαi affinity activated VLA-4 integrin adhesion
in two cell line constructs, U937FPR and U937FPR∆ST. Both cells lines express the
Gαi coupled formyl peptide receptor. U937FPR cells express a wild-type version of
the receptor and U937FPR∆ST cells express a non-desensitizing mutant of the receptor which maintains high VLA-4 affinity after stimulation with fMLF chemokine.
VLA-4 ligands for these experiments were LDV-FITC and VCAM-1 a natural ligand
expressed on B78H1 mouse melanoma cells.
To monitor association and dissociation cells U937FPR (Figure 6a) or U937FPR∆ST
(Figure 6b) were first incubated with 8 nM LDV-FITC probe. Next, the cells were
stimulated; addition of DMSO caused maintenance of basal fluorescence and addition of fMLF at saturating concentration to cause high affinity activation increased
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(a)

(b)

(c)

Figure 6: Real Time Association and Dissociation of LDV-FITC and B78H1
cells in response to thioridazine: (a) U937FPR or (b) U937FPR∆ST association
with 8 nM LDV-FITC after stimulation with 100 nM fMLF or DMSO(•) followed
by dissociation after blocking with DMSO(•), LDV(•), or 7.5 µM thioridazine(•);
and, (c) U937FPR∆ST and B78H1VCAM-1 cell aggregation following stimulation
with 100 nM fMLF and dissociation after blocking with DMSO(•), LDV(•), 10 µM
thioridazine(•), or 50 µM thioridazine(•).

binding of LDV-FITC. Following the stimulation with fMLF, peak fluorescence was
established. Samples were then treated with DMSO, 1 uM non-fluorescent LDV or
7.5 uM thioridazine. The addition of thioridazine reduced fluorescent signal to below
basal levels and at a faster rate than blocking with LDV. The loss of fluorescence
appeared only slightly faster in U937FPR cells compared to the non-desensitizing
U937FPR∆ST cells.
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Next, a similar activation strategy was tested in a method one step closer to
the native pathway with VCAM-1 expressing B78H1 cells (Figure 6c). Red stained
U937FPR∆ST cells were incubated with green stained B78H1 cells causing contact
and adhesion of the two cell types. Data were collected as double positive red-green
events/10 sec as a measure of VCAM-1 association with VLA-4. Again samples
were stimulated with fMLF to activate VLA-4 integrins and to increase association
events. After peak association, DMSO, 1 uM LDV, 10 uM thioridazine, or 50 uM
thioridazine was added and dissociation was then monitored. Here, the 10 uM dose
of thioridazine showed decreased dissociation compared to LDV. Increasing the concentration of thioridazine to 50 uM caused an incremental effect showing slightly
more dissociation than LDV. Thus, together thioridazine was able to disrupt the
high affinity association of VLA-4 integrin with both a small molecule ligand and
with native ligand.

3.2

Thioridazine blocks Gαi chemokine mediated chemotaxis.

Thioridazine was next assessed for its ability to alter homing in vitro using chemotaxis. Chemotaxis utilizes specially designed porous chambers which allow cells to
migrate towards chemokine gradients in a bottom chamber. Successful migration
requires cell polarization and motility to reach and pass through the small pores.
To examine chemotaxis first wild type U937FPR and mutant U937FPR∆ST migration were compared using the two separate chemokines fMLF and SDF-1α to induce
chemotaxis (Figure 7a). The U937 cells were added to the upper wells of chemotaxis chambers with lower chambers containing media and PBS, SDF-1α or fMLF.
After four hours, cells in lower chambers were counted and compared to the number
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(a)

(b)

(c)

Figure 7: Effects of thioridazine on U937 cell migration: (a) U937FPR∆ST()
and U937FPR() chemotaxis to PBS, 100 nM fMLF, or 12.5 nM SDF-1α; (b)
U937FPR cell chemotaxis to 100 nM fMLF or 12.5 nM SDF-1α inhibited with
PBS(), 65 µM AMD(), or 25 µM thioridazine( ); and, (c) U937FPR chemotaxis to 100 nM fMLF with increasing concentrations of thioridazine.

of cells loaded into upper chambers to calculate percent migration. Results indicated U937FPR cells could migrate in response to both fMLF and SDF-1α whereas,
U937FPR∆ST cells only migrated toward SDF-1α. Previous research has demonstrated the ST mutants do migrate towards fMLF but an inability to desensitize
prevents release into the lower chamber (Zigmond and Hirsch, 1973). Thus this experiment may reflect the importance of integrin adhesion in chemotaxis.
Next, thioridazine was used in the assay to determine if the it could alter SDF-
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1α or fMLF mediated chemotaxis (Figure 7B). U937FPR cells were placed in upper
chambers containing DMSO, 65 uM AMD3100 or 25 µM thioridazine with lower
chambers containing media and SDF-1α or fMLF. The assays were again run for
four hours and percent migration was calculated for each of the chambers. SDF-1α
chemotaxis was inhibited by both AMD3100 and thioridazine while fMLF chemotaxis was inhibited only with thioridazine. Multiple concentrations of thioridazine
were then tested to attain the EC50 dose for inhibition of fMLF mediated chemotaxis
(Figure 7C). Statistical results indicated a 12 µM EC50 for inhibition of migration.
Thus thioridazine was able to inhibit chemotaxis to multiple Gαi coupled chemokines
at ≈ 10−5 molar concentrations.

3.3

Thioridazine alters intracellular calcium signaling.

(a)

(b)

Figure 8: Real time measurements of intracellular calcium mobilization
response to thioridazine: (a) Calcium mobilization in U937FPR following stimulation with 100 nM fMLF only (•) or fMLF stimulation followed by either DMSO
(•) or 25 µM thioridazine (•); and, (b) calcium mobilization with 100 nM fMLF only
(•) or after pre-incubation with DMSO (•) or 25 µM thioridazine (•) for 3 minutes.
Next, to determine the impact of thioridazine on intracellular signaling flow cytometry experiments were conducted to monitor intracellular calcium (intracellular
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Ca2+ ) mobilization. Cell stimulation with fMLF is known to cause a spike intracellular Ca2+ which correlates to VLA-4 extension and increased affinity (Chigaev
et al., 2007). Here thioridazine was added prior to or following fMLF stimulation to
determine the impact on intracellular Ca2+ . U937FPR cells were labeled with the
green fluorescent intracellular Ca2+ probe fluo-4. The fluo-4 probe displays increased
fluorescent emission upon binding calcium. This change in fluo-4 signaling was monitored in real-time with flow cytometry. Calcium was mobilized with excess fMLF
which caused a rapid 5-fold spike in fluorescence signal. The addition of thioridazine
resulted in two different observations. In experiments where thioridazine was added
following stimulation (Figure 8a), the fluorescent signal was immediately abrogated
to the baseline level. In experiments where thioridazine was added 3 minutes prior
to stimulation (Figure 8b), fMLF mediated signaling was only partially reduced. Together, the results indicate that thioridazine does antagonize the signaling related to
Gαi integrin activation.

3.4

Thioridazine mobilizes hematopoietic progenitor populations in vivo.

Previous studies suggested HSC mobilization could serve as model to determine if in
vitro integrin inhibition could translate to in vivo conditions. Here thioridazine was
compared side by side with AMD3100 mobilization as a positive control in murine
hematopoietic progenitor cell mobilization. Mice were administered doses of vehicle, AMD3100, or thioridazine. Blood was collected for assessment one hour post
injection. First nucleated cell counts were gathered after lysing the red blood cells
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(a)

(b)

(c)

(d)

Figure 9: Hematopoietic progenitor cell mobilization in response to thioridazine or AMD3100: (a) Displays total white blood cell/mL counts in response
to a 1-hour dose of thioridazine or AMD3100 in C57BL6 mice; (b) Release of colony
forming cells in response to a one hour dose of thioridazine or AMD3100; (c) Representative dark-field images of CFU colonies displaying the background white blood
cell levels in thioridazine treated mice(left) compared to AMD3100 treated mice
(right); and, (d) Colony forming cell counts displayed relative to white cell counts
displayed as a percentage of CFU/mL.

(Figure 9a). AMD3100 showed significantly increased white/nucleated blood cells
compared to both vehicle and thioridazine. Next, cells were counted and plated for
colony forming unit(CFU) assays. CFU plates were processed following 14 days of
incubation by enumerating individual colonies. These counts were quantified based
on plate load and total white blood cells per mL to give total CFU/mL counts (Figure 9b). Results indicated that thioridazine caused increased colonies, three fold
higher, relative to vehicle but not as markedly as AMD3100, which showed a six fold
increase in colonies over vehicle.
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The discrepancy, however, between AMD3100 mobilization which showed much
higher WBC counts relative to thioridazine and vehicle indicated perhaps that AMD3100
was having a broader effect on leukocyte populations. Representative photographs of
CFU colonies were taken to demonstrate the large difference in the peripheral WBC
cells between thioridazine treated mice and AMD3100 treated mice (Figure 9c). Data
was then reassessed to normalize the CFU counts/WBC counts (Figure 9d). The
normalized counts indicated that the relative percentage of progenitor cells/mL of
blood were similar between AMD3100 and thioridazine. While total mobilization
with AMD3100 is still higher thioridazine causes a more enriched progenitor and
stem cell population. Thus together thioridazine does mobilize colony forming cells
but with a lack of the broad leukocyte mobilization seen with AMD3100.

3.5

Thioridazine kills B-ALL cells independent of VCAM-1
and the anti-cancer drug Ara-C.

To determine the impact of allosteric VLA-4 inhibition in cancer treatment cell viability was assessed in B-ALL Nalm-6 cells seeded on rVCAM following overnight
treatment with thioridazine (Figure 10). Previous studies have demonstrated attachment to fibronectin, VCAM-1 or stromal cells causes anti-cancer drug resistance
in AML, ALL and MM cell lines. Here, Nalm-6 cells were pre-incubated in cell
culture plates seeded with recombinant VCAM-1. Four hours later, DMSO, Ara-C
(cytosine-arabinoside) or varying concentrations of thioridazine were added and the
plates were incubated overnight. Following the 24 hour incubation, cell viability was
measured for each sample. Incubation with Ara-C stopped proliferation and lowered
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viability slightly. Thioridazine displayed a dose dependent toxicity starting at the
10 µM dose. This matched a previous study which tested thioridazine toxicity in
multiple leukemic cell lines Zhelev et al. (2004). Seeding with rVCAM-1 had no
effect on drug resistance even when testing other methods to elicit VCAM-1 rescue.
The other tests included altering thioridazine exposure time, pre-incubation times,
VCAM-1 concentration and the removal of unattached cells (unpublished). Thus
these results indicate that thioridazine is toxic to B-ALL cells over 24 hour periods
starting at low 10−5 molar concentrations.

Figure 10: Nalm-6 cell viability in response to treatment with thioridazine
or Ara-C: Displays the viability of Nalm-6 cells (B-ALL cell line) following 24 hour
treatment using the anti-cancer drug Ara-C or various concentrations of thioridazine.
The drugs were tested for integrin-adhesion induced resistance with() rVCAM-1
seeding or without().
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4

Discussion

4.1

Effects of phenothiazines on VLA-4 affinity and cell adhesion.

The properties and kinetics of VLA-4 activation have been well characterized by
previous studies using undifferentiated U937 cells in a model system (Chigaev et al.,
2007). More recently a HUTS-21 based primary drug screen and pilot study established that thioridazine and other phenothiazines can reduce HUTS-21 binding,
LDV-FITC binding, and VCAM-1 dependent aggregation using the same model system (Chigaev et al., 2011). In this study, thioridazine was further tested following
Gαi stimulation which is known to cause both increased ligand affinity and integrin
extension through intracellular signaling pathways (Chigaev et al., 2009). The stimulation of these two integrin properties has multiple implications in vivo including
cellular tethering, firm adhesion, homing, and localization. The results here demonstrated that thioridazine still reduces both LDV-FITC binding and VCAM-1 dependent aggregation following stimulation with a Gαi signal inducing chemokine(Figure
6).
Furthermore, these experiments found the loss of LDV-FITC binding signal using thioridazine to be accelerated relative to the loss of fluorescence using unlabeled
LDV (Figure 6a, 6b). A similar accelerated off rate has been shown previously in a
study using the compound U-73122, known as a phospholipase C inhibitor (Chigaev
et al., 2007). The comparable off rate to U-73122 may be a clue as to the mechanism
of action and target by which thioridazine modulates VLA-4. Interestingly, U-73122
has also been shown to inhibit neutrophil and platelet aggregation (Bleasdale et al.,
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1990). Together these results indicate allosteric antagonists such as thioridazine can,
in this Gαi stimulation model cause accelerated inhibition of VLA-4 related adhesion
relative to direct VLA-4 compounds such as LDV.
Of note, an increased concentration of thioridazine was required to disaggregate
B78H1-VCAM-1 from the U937 cells (Figure 6c). Initially, at the 10 µM concentration thioridazine did reduce aggregation but less so than LDV. Once thioridazine
concentration was increased to 50 µM the initial rate of disaggregation was similar
to that of the LDV-FITC off rate. It is important to take this finding into consideration since this model system is considered one step closer to the native pathway
of integrin cellular adhesion. The lowered efficacy seen here may suggest a potential
limitation to future studies concerning thioridazine’s therapeutic efficacy. One reason for the the decreased efficacy could be due to the multivalent interactions that
occur with aggregation relative to the single receptor-ligand interactions that occur
in the LDV-FITC experiments. Previous experiments have found that U937 cells
express approximately 55,000 VLA-4 receptors, while VCAM-1 transfected B78H1
cells averaged approximately 500,000 surface ligands (Zwartz et al., 2004). Since this
model is only a measure of complete disaggregation, the additional requirement to
interrupt multiple receptors for disaggregation is therefore one possible reason for
thioridazine’s reduced efficacy. The decreased efficacy could have also been caused
by non-specific binding between thioridazine and B78H1 cells. The B78H1 cells were
added at a three to one ratio with the U937 cells, which also increased total cell concentration by three fold per sample. If then, total thioridazine binding was similar
across the two cell types, the concentration difference alone could have accounted for
the decrease in efficacy.
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4.2

Effects of phenothiazines on intracellular signaling.

Intracellular Ca2+ signaling was assessed to investigate the mechanism by which
thioridazine was modulating VLA-4. The results showed that thioridazine significantly reduced intracellular Ca2+ levels in Gαi stimulated U937 cells (Figure 8a).
Following the addition of thioridazine the loss of intracellular Ca2+ fluorescent signal
was seen as instantaneous relative to the precision of the experiment. The loss of
signal appears to correlate with the rapid off rates observed in the LDV-FITC and
B78H1 experiments (Figure 6a, 6b). Intracellular Ca2+ flux is known to be a key
signal in the integrin activation pathway caused by Gαi stimulation. It is known
to contribute to the molecular unbending of VLA-4 and subsequently mediate both
cellular arrest and firm adhesion.
The rapid loss of intracellular Ca2+ signal is similar to results from two previous
studies, both using the aforementioned phospholipase C inhibitor, U-73122 (Chigaev
et al., 2007; Hyduk et al., 2007). The continued similarities between this phopholipase C inhibitor and thioridazine suggests signaling disruption as a possible pathway
through which thioridazine disrupts Gαi activated VLA-4 integrin. However, in the
initial pilot study thioridazine altered resting state VLA-4 integrin on unstimulated
U937 cells, but as shown in Figure 8, prior to Gαi stimulation U937 cells have only
limited basal levels of free intracellular Ca2+ (Chigaev et al., 2011). Together, these
findings indicate there are potentially two mechanisms by which thioridazine can
modulate VLA-4. One mechanism, shown here, which disrupts signaling related to
activated VLA-4 integrin, and the second mechanism, which allosterically inhibits
VLA-4 in the resting state. Considering that phenothiazines have been tied to numerous receptors and widespread activities against various diseases this possibility of
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multiple activities related to VLA-4 is within reason (Sudeshna and Parimal, 2010;
Ohlow and Moosmann, 2011). Still, the counter argument exists that the mechanism
affecting the resting state also affects the activated state. As of now, U-73122 has
not been tested under resting conditions. It is therefore possible that U-73122 also
acts as an allosteric inhibitor in the resting state. To make the distinction the first
study should be to investigate known phospholipace C inhibitors, such as U-73122,
to determine if they can also affect resting VLA-4 similarly to thioridazine. Future
studies should also aim to uncover the activities related to thioridazine’s resting
state allosteric modulation. Temperature, has already been shown to have no effect on disruption, further studies could examine thioridazine’s effects on mechanical
conformation and whole cell membrane potential. (Chigaev et al., 2011).

4.3

Effects of phenothiazines on cellular motility.

The Gαi chemokines which upregulate VLA-4 affinity and extension also create diffuse gradients in vivo which induce cellular polarity, and cause cellular localization.
As such, the next set of experiments assessed the impact of thioridazine on in vitro
chemokine induced cellular motility. Since AMD3100 was planned as the positive
control for the in vivo HSC mobilization experiments, these chemotaxis assays were
performed comparing thioridazine’s impact on cell motility with AMD3100. Here,
thioridazine inhibited mobilization to two separate Gαi chemokines while AMD3100
only inhibited SDF-1α mobilization (Figure 7b). Taken together with the flow cytometry experiments these results further suggest thioridazine inhibits Gαi mediated
chemotaxis through the broad inhibition of adhesion signaling while AMD3100 only
impacts signaling through its known target, the CXCR-4 receptor. For complete-
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ness a comparison study was conducted between U937FPR∆ST and U937FPR cells
which indicated the importance of steady state activation of the Gαi receptors during
motility (Figure 7a). As has been described previously the U937FPR∆ST cells appeared unable to detach from the transwell inserts due to the constitutive activation
mediated by the ST variant of the FPR receptor.

4.4

Potential for blocking VLA-4 with phenothiazines in cancer treatment.

Previous studies had found that both AMD3100 and VLA-4 antibodies were capable
of potentiating Ara-C cytotoxicity against attached leukemic cell lines (Zeng et al.,
2009; Matsunaga et al., 2003). In this study thioridazine alone markedly decreased
cell viability of a B-cell acute lymphoblastic leukemia cell line over a 24-hour period
in both the presence and absence of VCAM-1 (Figure 10). Compared to the initial
prediction that thioridazine would serve to potentiate Ara-C toxicity these results
were unexpected. Both the cytotoxicity of thioridazine and the lack of VCAM-1 mediated resistance raised concern. A re-examination of previous studies did however
indicate that drug resistance can vary depending on the particular cancer cell lines,
and the VLA-4 substrate ligands, among which are fibronectin, stromal cells, and
VCAM-1(Mudry et al., 2000). It is therefore possible that the rVCAM-1 used here
was not the correct ligand to mediate resistance. Thus, while there is previous evidence for phenothiazine use against hematological malignancy, in this study VLA-4
inhibition was not confirmed as the mechanism (Jones, 1996). A follow-up study
using alternate cell lines and the correct VLA-4 ligands would hopefully address the
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limited result seen here.
The other concern raised from these experiments was cytotoxicity. This, however, was also addressed in a previous study which demonstrated that thioridazine
also shows a cytotoxic effect in seven other leukemic cell lines (Zhelev et al., 2004).
Initially that would be of considerable concern, however, the researchers also tested
thioridazine against normal lymphocytes and found no decrease in viability and actually saw an increase in ATP production at higher concentrations of drug. This
information along with the knowledge that thioridazine and other phenothiazines
have been administered chronically in patients at higher peak blood concentration
than the toxicity level found here suggests cytotoxicity may only be relevant to certain cell populations. With respect to the current study, the rapid changes seen in
integrin modulation during the flow cytometry experiments were likely unaffected by
cytotoxicity since each experiment only had minutes of exposure. There is however,
the potential that cytotoxicity played a role in the 4-hour chemotaxis experiments.

4.5

Effects of phenothiazines on HSC mobilization.

Hematopoietic stem cell mobilization was chosen as the in vivo method to test phenothiazine allosteric-modulation of VLA-4 integrin due to the availability of positive
controls, previous studies showing VLA-4 expression on the HSC populations, and
studies already using direct VLA-4 ligand compounds for mobilization. AMD3100
was used as the positive control due to its well established dose of 5mg/kg and
1-hour time course for peak mobilization. Thioridazine’s ability to rapidly dissociate ligand during in vitro work suggested a similar time course to AMD3100 would
work. Results from these experiments demonstrated that thioridazine could signifi-

40

cantly increase CFU counts relative to vehicle controls, however, total mobilization
was significantly lower than AMD3100 mobilization (Figure 9b 9d). Interestingly,
white cell counts obtained prior to CFU plating indicate AMD3100 was not only
mobilizing progenitors but also large quantities of additional leukocytes (Figure 9a).
Thioridazine meanwhile showed no difference in white cell count compared to vehicle. The varied effectiveness further indicates different mechanisms of action for
thioridazine and AMD3100 mobilization. The data suggests that thioridazine has a
reduced impact on total leukocyte populations and more focally impacts stem cell
populations relative to AMD3100. One reason for this may be due to the increased
VLA-4 expression shown previously on early progenitor cells compared to mature
leukocytes (Wagers et al., 2002).
Peak HSC mobilization by thioridazine was lower than that of AMD3100 and
BIO5192, which was used in a previous study at Washington University in St. Louis
(Ramirez et al., 2009). This lower outcome was unexpected following the relatively
increased effects of thioridazine in the in vitro experiments. A reassessment of the
hypothesis relative to these results suggests a number of reasons for reduced mobilization. First, thioridazine blocked chemotaxis to multiple Gαi chemokines compared
to AMD3100 which only inhibited SDF-1α chemotaxis. Thioridazine also caused a
rapid reduction in intracellular Ca2+ signaling. Initially both of these results were
thought to be positive indicators of thioridazine’s potential in vivo, however, it now
seems that while thioridazine can rapidly inhibit integrins, the broad reduction in
Gαi signaling may be effectively causing cellular paralysis. In other words, it’s likely
that the stem cells detached but without Gαi signaling along with the reduced blood
flow in the bone marrow niche it may have been unlikely for the cells to enter the
blood stream in high numbers. The second explanation for reduced mobilization
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could be related to the untested variables dose and time. The optimal time course
for AMD3100 mobilization is one hour, the optimal time course for BIOM5192 mobilization was thirty minutes to one hour, and previous work with antibodies has
shown peak mobilization at 24 hours (Ramirez et al., 2009; Broxmeyer et al., 2005;
Papayannopoulou and Nakamoto, 1993). Here, we only tested one hour time courses
for both thioridazine and AMD3100. An important future experiment would be to
try other dosing strategies and different time courses to optimize the thioridazine
mobilization protocol. Finally, only five phenothiazines were tested in the primary
screen and pilot study from which thioridazine was chosen while over sixty phenothiazine compounds have been used clinically. Since thioridazine’s efficacy was also
reduced going from the LDV-FITC model to the VCAM-1 aggregation model it is
suggestive that an alternate phenothiazine compound may produce a larger increase
in stem cell release.
Overall though, a positive result was achieved which is important for two reasons.
The first reason dates back to the observational study in the 1960’s which reported
increased atypical lymphocytes in phenothiazine treated patients (Fieve et al., 1966).
The clinicians who published the study mentioned in their discussion that the atypical lymphocytes may have been stem cells that had escaped into the blood. Their
data are comparable to the in vivo mice data seen here. Their data indicates a
two-fold increase in the percentage of circulating atypical cells relative to controls
while this data shows a two to three fold increase in colony forming units. Thus,
this study now answers the question as to why phenothiazine treatment increased
peripheral atypical lymphocyte numbers and confirms that the cells indeed represent stem cells or other early hematopoietic progenitor cells. These findings also
provide a reason why various blood dyscrasias can occur from phenothiazine treat-
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ment (Stübner et al., 2004). Combined these studies further affirm this relationship
between phenothiazines and cellular adhesion. The second important point is the
affirmation of allosteric VLA-4 modulation as a potential target in vivo. While the
final result with phenothiazine may be due to a the broad inhibition of adhesion
signaling each experiment in the study was carried out based on previous work using
direct VLA-4 antibodies and small molecule modulators.

4.6

Conclusions

The progression of integrin-directed compounds into clinical trials has been slow with
current pharmacological agonists, many of which were developed when integrins were
not fully understood (Cox et al., 2010). This study has built on a ten year effort into
the understanding of VLA-4 structure and regulation which yielded the discovery
of the first known allosteric VLA-4 antagonists potentially representing much better
clinical compounds in a number of therapies. The aims were to further characterize the relationship of these novel compounds to VLA-4 modulation and translate
the activity to an in vivo animal model of hematopoietic stem cell mobilization.
Experiments were conducted in a stepwise fashion beginning with well-established
in vitro models addressing adhesion relevant to the current understanding of HSC
mobilization. The results here have established potential for VLA-4 inhibition with
phenothiazines against a number of adhesion events including rolling, tethering, firm
adhesion, resting adhesion, homing, extravasion, inside-out and outside-in signaling.
Due to the long clinical history of phenothiazines these results have also yielded answers to multiple questions concerning side effects of treatment with phenothiazines
dating back over forty years. Characterization of this novel relationship also suggests
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why both VLA-4 and phenothiazines are being studied and patented independently
in a number of the same autoimmune disorders. Further, the similar effects on both
intracellular calcium signaling and LDV-FITC fluorescence suggests a link between
thioridazine and U-73122 the phospholipase C inhibitor. This finding could potentially represent a previously unknown mechanism and target for phenothiazine action, a topic that is still very controversial in over a century of phenothiazine clinical
use (Sudeshna and Parimal, 2010; Ohlow and Moosmann, 2011). The broad inhibition of resting VLA-4, activated VLA-4, intracellular Ca2+ , and cellular motility
indicate why phenothiazines may have such diverse clinical and therapeutic efficacy.
Ultimately, thioridazine was successfully translated to an in vivo model of HSC mobilization in mice confirming the potential for allosteric VLA-4 modulation in vivo.
Numerous future experiments will be needed to optimize mobilization, determine
effects on other integrins, further address the phospholipase C relationship and establish models in other therapies including cancer.
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